Research & Literature

[CALR gene mutation detection and clinical observation of 150 essential thrombocythemia patients].

Zhang X, Zhou M, Chao H, et al.

Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 2015; (36(5)):378-82 doi:10.3760/cma.j.issn.0253-2727.2015.05.005.

Calreticulin Mutated Essential Thrombocythemia Presenting as Acute Coronary Syndrome.

Nazha B, Garcia G, Kandov R, Odaimi M

Case reports in hematology 2015; (2015()):161764 doi:10.1155/2015/161764.

Long-term follow-up of essential thrombocythemia patients treated with anagrelide: subgroup analysis according to JAK2/CALR/MPL mutational status.

Mela Osorio MJ, Ferrari L, Goette NP, et al.

European journal of haematology 2016; (96(4)):435-42 doi:10.1111/ejh.12614.

Advances and challenges in the management of essential thrombocythemia.

Birgegård G

Therapeutic advances in hematology 2015; (6(3)):142-56 doi:10.1177/2040620715580068.

Myeloproliferative Neoplasms: A Contemporary Review.

Tefferi A, Pardanani A

JAMA oncology 2015; (1(1)):97-105 doi:10.1001/jamaoncol.2015.89.

DNMT3A mutations occur early or late in patients with myeloproliferative neoplasms and mutation order influences phenotype.

Nangalia J, Nice FL, Wedge DC, et al.

Haematologica 2015; (100(11)):e438-42 doi:10.3324/haematol.2015.129510.

Essential Thrombocythemia and Polycythemia Vera: Focus on Clinical Practice.

Tefferi A, Barbui T

Mayo Clinic proceedings 2015; (90(9)):1283-93.

Essential Thrombocythemia: The Dermatologic Point of View.

Cozzani E, Iurlo A, Merlo G, et al.

Clinical lymphoma, myeloma & leukemia 2015; (15(12)):739-47.

Clinical impact of bone marrow morphology for the diagnosis of essential thrombocythemia: comparison between the BCSH and the WHO criteria.

Gisslinger H, Jeryczynski G, Gisslinger B, et al.

Leukemia 2016; (30(5)):1126-32 doi:10.1038/leu.2015.360.

Contemporary approach to essential thrombocythemia and polycythemia vera.

Aruch D, Mascarenhas J

Current opinion in hematology 2016; (23(2)):150-60 doi:10.1097/MOH.0000000000000216.

Validation of the revised International Prognostic Score of Thrombosis for Essential Thrombocythemia (IPSET-thrombosis) in 585 Mayo Clinic patients.

Haider M, Gangat N, Lasho T, et al.

American journal of hematology 2016; (91(4)):390-4 doi:10.1002/ajh.24293.

Activation of the thrombopoietin receptor by mutant calreticulin in CALR-mutant myeloproliferative neoplasms.

Araki M, Yang Y, Masubuchi N, et al.

Blood 2016; (127(10)):1307-16 doi:10.1182/blood-2015-09-671172.

Pegylated interferon alpha-2a for essential thrombocythemia during pregnancy: outcome and safety. A case series.

Beauverd Y, Radia D, Cargo C, et al.

Haematologica 2016; (101(5)):e182-4 doi:10.3324/haematol.2015.139691.

[Treatment outcome of patients with essential thrombocythemia at our department in Hungary].

Iványi JL, Marton É, Plander M, Szendrei T

Orvosi hetilap 2016; (157(9)):336-41 doi:10.1556/650.2016.30323.

Myocardial infarction as a thrombotic complication of essential thrombocythemia and polycythemia vera.

Pósfai É, Marton I, Borbényi Z, Nemes A

Anatolian journal of cardiology 2016; (16(6)):397-402 doi:10.14744/AnatolJCardiol.2015.6125.

Thrombotic risk correlates with mutational status in true essential thrombocythemia.

Bertozzi I, Peroni E, Coltro G, et al.

European journal of clinical investigation 2016; (46(8)):683-9 doi:10.1111/eci.12647.

How I treat essential thrombocythemia.

Rumi E, Cazzola M

Blood 2016; (128(20)):2403-2414 doi:10.1182/blood-2016-05-643346.

Management of extreme thrombocytosis in myeloproliferative neoplasms: an international physician survey.

Koren-Michowitz M, Lavi N, Ellis MH, et al.

Annals of hematology 2017; (96(1)):87-92 doi:10.1007/s00277-016-2826-4.

MPL mutations and palpable splenomegaly are independent risk factors for fibrotic progression in essential thrombocythemia.

Haider M, Elala YC, Gangat N, et al.

Blood cancer journal 2016; (6(10)):e487 doi:10.1038/bcj.2016.98.

Primary myelofibrosis: 2017 update on diagnosis, risk-stratification, and management.

Tefferi A

American journal of hematology 2016; (91(12)):1262-1271 doi:10.1002/ajh.24592.

Update from the latest WHO classification of MPNs: a user's manual.

Passamonti F, Maffioli M

Hematology. American Society of Hematology. Education Program 2016; (2016(1)):534-542 doi:10.1182/asheducation-2016.1.534.

Application of prognostic score IPSET-thrombosis in patients with essential thrombocythemia of a Brazilian public service.

Navarro LM, Trufelli DC, Bonito DR, et al.

Revista da Associacao Medica Brasileira (1992) 2016; (62(7)):647-651 doi:10.1590/1806-9282.62.07.647.

Approach to patients with essential thrombocythaemia and very high platelet counts: what is the evidence for treatment?

Falchi L, Bose P, Newberry KJ, Verstovsek S

British journal of haematology 2017; (176(3)):352-364 doi:10.1111/bjh.14443.

Efficacy of interferon-alpha in essential thrombocythemia during pregnancy.

Yoshida Y, Katsurada T, Nakabou Y, Kawabata H

Annals of hematology 2017; (96(5)):877-878 doi:10.1007/s00277-017-2946-5.

The prognostic relevance of serum lactate dehydrogenase and mild bone marrow reticulin fibrosis in essential thrombocythemia.

Mudireddy M, Barraco D, Hanson CA, et al.

American journal of hematology 2017; (92(5)):454-459 doi:10.1002/ajh.24689.

[Mutation of CALR Gene in Patients with Chronic Myeloproliferative Neoplasm and Its Clinical Significance].

Tang Q, Zhang XW, Xia L, Jiang NK

Zhongguo shi yan xue ye xue za zhi 2017; (25(1)):151-156 doi:10.7534/j.issn.1009-2137.2017.01.027.

Pegylated interferon alfa-2a in patients with essential thrombocythaemia or polycythaemia vera: a post-hoc, median 83 month follow-up of an open-label, phase 2 trial.

Masarova L, Patel KP, Newberry KJ, et al.

The Lancet. Haematology 2017; (4(4)):e165-e175 doi:10.1016/S2352-3026(17)30030-3.

Essential thrombocythemia: a review of the clinical features, diagnostic challenges, and treatment modalities in the era of molecular discovery.

Chuzi S, Stein BL

Leukemia & lymphoma 2017; (58(12)):2786-2798 doi:10.1080/10428194.2017.1312371.

Pre-PMF emerging as important subgroup of MPN.

Gisslinger H

Blood 2017; (129(24)):3142-3144 doi:10.1182/blood-2017-04-777805.

Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results.

Verstovsek S, Passamonti F, Rambaldi A, et al.

Blood 2017; (130(15)):1768-1771 doi:10.1182/blood-2017-02-765032.

NCCN Guidelines Insights: Myeloproliferative Neoplasms, Version 2.2018.

Mesa RA, Jamieson C, Bhatia R, et al.

Journal of the National Comprehensive Cancer Network : JNCCN 2017; (15(10)):1193-1207.

Current challenges in the management of essential thrombocythemia.

Kleman A, Singavi AK, Michaelis LC

Clinical advances in hematology & oncology : H&O 2017; (15(10)):773-783.

Marked elevation of serum lactate dehydrogenase in primary myelofibrosis: clinical and prognostic correlates.

Shah S, Mudireddy M, Hanson CA, et al.

Blood cancer journal 2017; (7(12)):657 doi:10.1038/s41408-017-0024-9.

Efficacy and safety of interferon alpha for essential thrombocythemia during pregnancy: two cases and a literature review.

Sakai K, Ueda A, Hasegawa M, Ueda Y

International journal of hematology 2018; (108(2)):203-207 doi:10.1007/s12185-017-2397-8.

JAK2 V617F hematopoietic clones are present several years prior to MPN diagnosis and follow different expansion kinetics.

McKerrell T, Park N, Chi J, et al.

Blood advances 2017; (1(14)):968-971 doi:10.1182/bloodadvances.2017007047.

Validation of previous prognostic models for thrombosis and exploration of modified models in patients with essential thrombocythemia.

Hashimoto Y, Nakamae H, Tanaka T, et al.

European journal of haematology 2018; (101(4)):508-513 doi:10.1111/ejh.13136.

Increased Dkk-1 plasma levels may discriminate disease subtypes in myeloproliferative neoplasms.

Mambet C, Necula L, Mihai S, et al.

Journal of cellular and molecular medicine 2018; (22(8)):4005-4011 doi:10.1111/jcmm.13753.

The comorbidity of acute ischemic stroke and splenic infarction resulting from essential thrombocythemia.

Yuan J, Wu Y, Hao J, Hu W

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2018; (39(10)):1787-1790 doi:10.1007/s10072-018-3462-7.

Philadelphia-negative myeloproliferative neoplasms as disorders marked by cytokine modulation.

Cacemiro MDC, Cominal JG, Tognon R, et al.

Hematology, transfusion and cell therapy 2018; (40(2)):120-131 doi:10.1016/j.htct.2017.12.003.

Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management.

Tefferi A, Barbui T

American journal of hematology 2019; (94(1)):133-143 doi:10.1002/ajh.25303.

Distinguishing essential thrombocythemia JAK2V617F from polycythemia vera: limitations of erythrocyte values.

Silver RT, Krichevsky S

Haematologica 2019; (104(11)):2200-2205 doi:10.3324/haematol.2018.213108.

Efficacy and safety of anagrelide as a first-line drug in cytoreductive treatment-naïve essential thrombocythemia patients in a real-world setting.

Ito T, Hashimoto Y, Tanaka Y, et al.

European journal of haematology 2019; (103(2)):116-123 doi:10.1111/ejh.13265.

Increased SLAMF7high monocytes in myelofibrosis patients harboring JAK2V617F provide a therapeutic target of elotuzumab.

Maekawa T, Kato S, Kawamura T, et al.

Blood 2019; (134(10)):814-825 doi:10.1182/blood.2019000051.

Targeted molecular characterization shows differences between primary and secondary myelofibrosis.

Courtier F, Garnier S, Carbuccia N, et al.

Genes, chromosomes & cancer 2020; (59(1)):30-39 doi:10.1002/gcc.22789.

Aquagenic pruritus in essential thrombocythemia is associated with a higher risk of thrombosis.

Le Gall-Ianotto C, Le Calloch R, Couturier MA, et al.

Journal of thrombosis and haemostasis : JTH 2019; (17(11)):1950-1955 doi:10.1111/jth.14588.

Comparison between thrombotic risk scores in essential thrombocythemia and survival implications.

Santoro M, Accurso V, Mancuso S, et al.

Hematological oncology 2019; (37(4)):434-437 doi:10.1002/hon.2670.

Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea.

Yacoub A, Mascarenhas J, Kosiorek H, et al.

Blood 2019; (134(18)):1498-1509 doi:10.1182/blood.2019000428.

Time for revival of the red blood cell count and red cell mass in the differential diagnosis between essential thrombocythemia and polycythemia vera?

Hasselbalch HC

Haematologica 2019; (104(11)):2119-2125 doi:10.3324/haematol.2019.229039.

From Budd-Chiari syndrome to acquired von Willebrand syndrome: thrombosis and bleeding complications in the myeloproliferative neoplasms.

Stein BL, Martin K

Blood 2019; (134(22)):1902-1911 doi:10.1182/blood.2019001318.

From Budd-Chiari syndrome to acquired von Willebrand syndrome: thrombosis and bleeding complications in the myeloproliferative neoplasms.

Stein BL, Martin K

Hematology. American Society of Hematology. Education Program 2019; (2019(1)):397-406 doi:10.1182/hematology.2019001318.

Cardiovascular Risk in Essential Thrombocythemia and Polycythemia Vera: Thrombotic Risk and Survival.

Accurso V, Santoro M, Mancuso S, et al.

Mediterranean journal of hematology and infectious diseases 2020; (12(1)):e2020008 doi:10.4084/MJHID.2020.008.

Increased von Willebrand factor levels in polycythemia vera and phenotypic differences with essential thrombocythemia.

Sacco M, Ranalli P, Lancellotti S, et al.

Research and practice in thrombosis and haemostasis 2020; (4(3)):413-421 doi:10.1002/rth2.12315.

Atypical Myocardial Infarction with Apical Thrombus and Systemic Embolism: A Rare Presentation of Likely JAK2 V617F-Positive Myeloproliferative Neoplasm.

Atere M, Al-Zakhari R, Collins J, et al.

Case reports in oncological medicine 2020; (2020()):9654048 doi:10.1155/2020/9654048.

Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management.

Tefferi A, Barbui T

American journal of hematology 2020; (95(12)):1599-1613 doi:10.1002/ajh.26008.

Portal vein thrombosis due to essential thrombocythemia with limited cutaneous systemic sclerosis.

Iwaki K, Ueda Y, Mishima M, et al.

Clinical journal of gastroenterology 2021; (14(1)):293-296 doi:10.1007/s12328-020-01274-6.

Mutational profiling in suspected triple-negative essential thrombocythaemia using targeted next-generation sequencing in a real-world cohort.

Michail O, McCallion P, McGimpsey J, et al.

Journal of clinical pathology 2021; (74(12)):808-811 doi:10.1136/jclinpath-2020-206570.

Hemorrhage in Essential Thrombocythemia or Polycythemia Vera: Epidemiology, Location, Risk Factors, and Lessons Learned from the Literature.

Nicol C, Lacut K, Pan-Petesch B, et al.

Thrombosis and haemostasis 2021; (121(5)):553-564 doi:10.1055/s-0040-1720979.

Austrian recommendations for the management of essential thrombocythemia.

Buxhofer-Ausch V, Heibl S, Sliwa T, et al.

Wiener klinische Wochenschrift 2021; (133(1-2)):52-61 doi:10.1007/s00508-020-01761-3.

The risk of thrombosis in essential thrombocythemia is associated with the type of CALR mutation: A multicentre collaborative study.

Pérez Encinas MM, Sobas M, Gómez-Casares MT, et al.

European journal of haematology 2021; (106(3)):371-379 doi:10.1111/ejh.13561.

The Essential Thrombocythemia in 2020: What We Know and Where We Still Have to Dig Deep.

Accurso V, Santoro M, Mancuso S, et al.

Clinical medicine insights. Blood disorders 2020; (13()):2634853520978210 doi:10.1177/2634853520978210.

Combination of myeloproliferative neoplasm driver gene activation with mutations of splice factor or epigenetic modifier genes increases risk of rapid blastic progression.

Bartels S, Vogtmann J, Schipper E, et al.

European journal of haematology 2021; (106(4)):520-528 doi:10.1111/ejh.13579.

Epidemiology of the Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms.

Shallis RM, Zeidan AM, Wang R, Podoltsev NA

Hematology/oncology clinics of North America 2021; (35(2)):177-189 doi:10.1016/j.hoc.2020.11.005.

Murine Modeling of Myeloproliferative Neoplasms.

Chen K, Shih AH

Hematology/oncology clinics of North America 2021; (35(2)):253-265 doi:10.1016/j.hoc.2020.11.007.

Low-Risk Essential Thrombocythemia: A Comprehensive Review.

Robinson AJ, Godfrey AL

HemaSphere 2021; (5(2)):e521 doi:10.1097/HS9.0000000000000521.

Mutations and thrombosis in essential thrombocythemia.

Guglielmelli P, Gangat N, Coltro G, et al.

Blood cancer journal 2021; (11(4)):77 doi:10.1038/s41408-021-00470-y.

Clinical and Laboratory Features of JAK2 V617F, CALR, and MPL Mutations in Malaysian Patients with Classical Myeloproliferative Neoplasm (MPN).

Zulkeflee RH, Zulkafli Z, Johan MF, et al.

International journal of environmental research and public health 2021; (18(14)) doi:10.3390/ijerph18147582.

Changes in the incidence and overall survival of patients with myeloproliferative neoplasms between 2002 and 2016 in the United States.

Verstovsek S, Yu J, Scherber RM, et al.

Leukemia & lymphoma 2022; (63(3)):694-702 doi:10.1080/10428194.2021.1992756.

A toe ulcer in a patient with essential thrombocythemia successfully treated with a combination of anagrelide and prednisolone.

Sugai T, Yamaguchi Y, Narahira A, et al.

Dermatologic therapy 2022; (35(2)):e15221 doi:10.1111/dth.15221.

Essential Thrombocythemia in Children and Adolescents.

Putti MC, Bertozzi I, Randi ML

Cancers 2021; (13(23)) doi:10.3390/cancers13236147.

Coexistence of Prefibrotic Myelofibrosis with Monoclonal Gammopathy of Undetermined Significance: A Case Report.

Ismail OM, Amer A, Ibrahim FA, et al.

Case reports in oncology 2021; (14(3)):1435-1440 doi:10.1159/000516746.

High Rate of Obstetric Complications in Patients With Essential Thrombocythemia.

İskender D, Yılmaz-Ergani S, Aksoy M, et al.

Cureus 2021; (13(12)):e20449 doi:10.7759/cureus.20449.

Lab tests for MPN.

Moncada A, Pancrazzi A

International review of cell and molecular biology 2022; (366()):187-220 doi:10.1016/bs.ircmb.2021.02.010.

Targets in MPNs and potential therapeutics.

Levy G, Mambet C, Pecquet C, et al.

International review of cell and molecular biology 2022; (366()):41-81 doi:10.1016/bs.ircmb.2021.06.004.

Thrombotic events and mortality risk in patients with newly diagnosed polycythemia vera or essential thrombocythemia.

Pemmaraju N, Gerds AT, Yu J, et al.

Leukemia research 2022; (115()):106809 doi:10.1016/j.leukres.2022.106809.

Increased cleavage of von Willebrand factor by ADAMTS13 may contribute strongly to acquired von Willebrand syndrome development in patients with essential thrombocythemia.

Kubo M, Sakai K, Hayakawa M, et al.

Journal of thrombosis and haemostasis : JTH 2022; (20(7)):1589-1598 doi:10.1111/jth.15717.

Essential thrombocythemia with CALR mutation and recurrent stroke: two case reports and literature review.

Chen R, Shi X, Wang L, et al.

Therapeutic advances in neurological disorders 2022; (15()):17562864221092093 doi:10.1177/17562864221092093.

Excess mortality in younger patients with myeloproliferative neoplasms.

Abu-Zeinah K, Saadeh K, Silver RT, et al.

Leukemia & lymphoma 2023; (64(3)):725-729 doi:10.1080/10428194.2022.2070914.

Classic myeloproliferative neoplasms in Singapore: A population-based study on incidence, trends, and survival from 1968 to 2017.

Htun HL, Lian W, Wong J, et al.

Cancer epidemiology 2022; (79()):102175 doi:10.1016/j.canep.2022.102175.

Hematological relevance of JAK2 V617F and calreticulin mutations in Tunisian patients with essential thrombocythemia.

Abdelghani M, Hammami H, Zidi W, et al.

Journal of clinical laboratory analysis 2022; (36(8)):e24522 doi:10.1002/jcla.24522.

Splenic Infarct as the Presenting Manifestation of Essential Thrombocythemia.

Khade S, Khera S, Varshney VK, et al.

Ochsner journal 2022; (22(2)):188-191 doi:10.31486/toj.21.0073.

Validation of thrombotic risk factors in 1381 patients with essential thrombocythaemia: A multicentre retrospective real-life study.

Stuckey R, Ianotto JC, Santoro M, et al.

British journal of haematology 2022; (199(1)):86-94 doi:10.1111/bjh.18387.

The differences of hemogram, myelogram, and driver gene mutations in classic myeloproliferative neoplasms.

Wang J, Zhang J, Huang J, et al.

Blood cells, molecules & diseases 2022; (97()):102698 doi:10.1016/j.bcmd.2022.102698.

Triple-Negativity Identifies a Subgroup of Patients with Better Overall Survival in Essential Thrombocythemia.

Santoro M, Accurso V, Mancuso S, et al.

Hematology reports 2022; (14(3)):265-269 doi:10.3390/hematolrep14030037.

Essential thrombocythemia: challenges in clinical practice and future prospects.

Godfrey AL, Green AC, Harrison CN

Blood 2023; (141(16)):1943-1953 doi:10.1182/blood.2022017625.

Reevaluation of cardiovascular risk factors for thrombotic events in 580 Japanese patients with essential thrombocythemia.

Furuya C, Hashimoto Y, Morishita S, et al.

Journal of thrombosis and thrombolysis 2023; (55(2)):263-272 doi:10.1007/s11239-022-02751-0.

A review of essential thrombocythemia and its complications.

Babakhanlou R, Masarova L, Verstovsek S

Clinical advances in hematology & oncology : H&O 2023; (21(2)):76-84.

Comparison of Clinical and Molecular Features Between Patients With Essential Thrombocythemia and Early/Prefibrotic Primary Myelofibrosis Presenting With Thrombocytosis in Taiwan.

Kuo MC, Chuang WY, Chang H, et al.

American journal of clinical pathology 2023; (159(5)):474-483 doi:10.1093/ajcp/aqac173.

Incidence of Thrombosis at Different Sites During the Follow-Up Period in Essential Thrombocythemia: A Systematic Review and Meta-Analysis.

Wang D, Yu X, Sun Y, et al.

Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2023; (29()):10760296231181117 doi:10.1177/10760296231181117.

Recurrent Stroke with Rapid Development of Intracranial Artery Stenosis and Subsequent Successful Mechanical Thrombectomy in Essential Thrombocythemia.

Kato Y, Iijima S, Kohyama S, et al.

Internal medicine (Tokyo, Japan) 2024; (63(6)):847-852 doi:10.2169/internalmedicine.2189-23.

Toe Gangrene as the First Presenting Symptom of Essential Thrombocythemia: A Case Report.

Altayyan MM, Abu-Tineh M, Alshurafa A, et al.

Cureus 2023; (15(7)):e42388 doi:10.7759/cureus.42388.

Same Syndrome, Different Causes and Treatment: Path to Diagnosis and Management of Two Interesting Cases of Acquired von Willebrand Syndrome.

Monti M, Massari E, Rosetti M, et al.

Seminars in thrombosis and hemostasis 2024; (50(2)):307-309 doi:10.1055/s-0043-1772837.

[Search for mutations in patients with Philadelphia negative myeloproliferative neoplasms in a public hospital in Chile].

Jaramillo I, Torres V, Leyton L, et al.

Revista medica de Chile 2022; (150(7)):849-854 doi:10.4067/s0034-98872022000700849.

Understanding triple negative myeloproliferative neoplasms: pathogenesis, clinical features, and management.

Tharakan S, Mascarenhas J, Tremblay D

Leukemia & lymphoma 2024; (65(2)):158-167 doi:10.1080/10428194.2023.2277674.

Essential thrombocythemia: 2024 update on diagnosis, risk stratification, and management.

Tefferi A, Vannucchi AM, Barbui T

American journal of hematology 2024; (99(4)):697-718 doi:10.1002/ajh.27216.

Case report: Peri-procedural hydroxyurea helps minimize bleeding in patients with Essential Thrombocythemia associated with acquired von Willebrand syndrome.

Kogan L, Price R, Kotchetkov R

Frontiers in oncology 2024; (14()):1326209 doi:10.3389/fonc.2024.1326209.

Impact of CALR and JAK2V617F Mutations on Clinical Course and Disease Outcomes in Essential Thrombocythemia: A Multicenter Retrospective Study in Turkish Patients.

Narlı Özdemir Z, İpek Y, Patır P, et al.

Turkish journal of haematology : official journal of Turkish Society of Haematology 2024; (41(1)):26-36 doi:10.4274/tjh.galenos.2024.2023.0430.

Acquired von Willebrand Syndrome in a 17-Year-Old With Essential Thrombocythemia: A Case Report With Literature Review.

Youn L, Kuta A, Srinivasan M, et al.

Cureus 2024; (16(3)):e55668 doi:10.7759/cureus.55668.

Polycythemia vera and essential thrombocythemia of intermediate-age: A real-life, multicenter analysis of first-line treatment approach.

Sobieralski P, Bieniaszewska M, Bołkun Ł, et al.

Advances in clinical and experimental medicine : official organ Wroclaw Medical University 2025; (34(1)):25-32 doi:10.17219/acem/182857.

Intravenous Immunoglobulin offers temporary improvement in acquired von Willebrand syndrome due to monoclonal gammopathy: A case report.

Zablonski KG, Rajkumar A, Nayak L

EJHaem 2024; (5(4)):833-837 doi:10.1002/jha2.969.

Reduced Platelet Activation in Triple-Negative Essential Thrombocythemia Compared with JAK2V617F-Mutated Essential Thrombocythemia.

Dong H, Chen J, Zhang J, et al.

Clinical cancer research : an official journal of the American Association for Cancer Research 2024; (30(23)):5473-5482 doi:10.1158/1078-0432.CCR-24-1731.

Gangrene and osteomyelitis of the toe in a previously healthy patient due to undiagnosed essential thrombocythemia.

Schick A, Dhamoon AS

BMJ case reports 2024; (17(10)) doi:10.1136/bcr-2024-261063.

Diagnostic challenges of high-grade myeloid malignancies with partial plasmacytoid dendritic cell differentiation: report of two cases with literature review.

Nahmod KA, Miranda RN, Vega F, et al.

Leukemia & lymphoma 2025; (66(4)):764-772 doi:10.1080/10428194.2024.2422846.

Anagrelide in the management of essential thrombocythemia: a systemic review and meta-analysis.

Abreu Lopez B, Arvelaez Pascucci J, Ramzy SM, et al.

International journal of hematology 2025; (122(1)):45-56 doi:10.1007/s12185-025-03959-5.

Massive Anterior STEMI Due to Essential Thrombocythemia Leading to Urgent Thrombocytapheresis.

Rioux AV, Morin L, Bernier M, et al.

JACC. Case reports 2025; (30(37)):105731 doi:10.1016/j.jaccas.2025.105731.

Risk of Transformation to Acute Myeloid Leukaemia and Myelodysplastic Syndromes in Patients With Myeloproliferative Neoplasms Over Attained Age and Time Since Diagnosis: A Nationwide Cohort Study.

Batyrbekova N, Landtblom AR, Hultcrantz M, et al.

European journal of haematology 2026; doi:10.1111/ejh.70141.